Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

Status unconfirmed · Phase 2

Conditions studied: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitts Leukemia/Lymphoma, Chronic Myelogenous Leukemia

In brief

CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.

Key facts

Study ID

NCT01513603

Run by

New York Medical College

People needed

50

Starts

2012-01-01

Expected to finish

2014-01-01

Last updated by the study team

2012-01-20

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed or refractory acute lymphoblastic leukemia,
• Burkitts leukemia/lymphoma,
• Lymphoid blastic CML,
• Lymphoblastic lymphoma.

Where it is running

• Westchester Medical Center/New York Medical College — Valhalla, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.